The cell surface receptor A v B 6 is epithelial specific, and its expression is tightly regulated; it is low or undetectable in adult tissues but has been shown to be increased in many different cancers, including pancreatic, cervical, lung, and colon cancers. Studies have described A v B 6 as a prognostic biomarker linked to poor survival. We have recently shown the feasibility of imaging A v B 6 in vivo by positron emission tomography (PET) using the peptide [
Introduction
In recent years, positron emission tomography (PET) imaging, using 2-[
18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG), has become routine for detection of tumors and monitoring of treatment response (1) (2) (3) . [ 18 F]FDG, a radiolabeled analogue of glucose, is taken up and trapped primarily in cells with high metabolism. As glucose hypermetabolism is commonly found in inflammation, as well as in many malignancies, distinguishing cancer from other hypermetabolic states remains a challenge (1, 4, 5) . Although PET has been combined with other imaging modalities, most notably computed tomography (CT), which relies on subtle differences in soft tissue density to distinguish between normal and malignant tissues (5-7), [
18 F]FDG-PET/CT still leaves considerable room for improvement in diagnosis and clinical management of many cancers (8) . The availability of more disease-specific imaging agents (7) could help to mitigate the limited specificity of [ 18 F]FDG for malignant tissue. Rather than relying on slight changes in tissue density or metabolic rate alone, targeting disease-specific tissue markers could considerably aid in tumor detection and localization. The feasibility of this approach has been shown with [ 18 F]galacto-RGD, a small radiolabeled peptide used for PET imaging of the cancer-related integrin a v h 3 (9) . In contrast to a v h 3 , other members of the integrin family have received relatively little attention. However, newly emerging evidence indicates that a v h 6 may also be an important target for diagnosis and treatment of cancer (10) (11) (12) (13) (14) . The integrin a v h 6 was first identified in a human pancreatic carcinoma cell line (15) . Subsequent studies established that although a v h 6 is epithelial specific, its expression is low or undetectable in healthy adult tissues. Up-regulation has been recognized during tissue remodeling, including inflammation and wound healing (16) (17) (18) . Significantly, expression has also been shown to be increased in many different cancers (13, 19) . Among gastroenteropancreatic adenocarcinomas, a v h 6 expression was found to be strongest in pancreatic ductal adenocarcinomas (PDAC; ref. 20) . Moreover, a v h 6 has recently been described as a prognostic indicator, with high levels of expression correlating with poor prognosis for cancer of the colon, cervix, lung, and stomach (10) (11) (12) 21) . Antibody-blockade of a v h 6 was shown to inhibit tumor progression in vivo in animal models (13) . Thus, mounting evidence implicates a v h 6 as an important and biologically relevant target for molecular imaging of cancer.
Recently, we showed the ability to selectively image a v h 6 -expressing tumors in vivo with microPET using the a v h 6 
Materials and Methods
Reagents and cell lines. Reagents, materials, and DX3puro/DX3puroh6 cell lines have been described previously (22) . Pancreatic cancer cell lines were obtained from American Type Culture Collection. Transforming growth factor h1 human latency-associated peptide (TGFh1-LAP) was purchased from Sigma. A Leica CM1850 cryostat (Leica Microsystems) was used for tissue sectioning.
Competitive binding ELISA. The in vitro efficacies of the peptides toward integrins a v h 6 , a v h 3 , a v h 5 , a 5 h 1 , and a IIb h 3 were analyzed by competitive binding ELISA as described previously (22) .
Flow cytometry. Integrin expression on the cell lines was determined as previously described (24) .
Cell binding and internalization. A cell suspension (3.75 Â 10 6 cells) was incubated with the radiotracer (0.2 ACi) in serum-free medium (pH 7.2, 100 AL). For each radiotracer, the cell lines were assayed concurrently (n = 4 samples per cell line per time point). The fraction of bound radioactivity was determined with a g-counter (cell pellet versus supernatant). To determine the fraction of internalized radioactivity, the cells were then treated with acidic wash buffer [0.2 mol/L sodium acetate, 0.5 mol/L sodium chloride (pH 2.5), 4jC] to release surface-bound activity (25) . The internalized fraction was determined with a g-counter (cell pellet versus radioactivity released into supernatant).
Xenograft cell lines and animal model. All animal studies were carried out using male athymic nude mice (nu/nu; Charles River Laboratories) following approved protocols. DX3puroh6 (a v h 6 positive) and DX3puro (control) cells were injected s.c. (n = 20 mice; 3 Â 10 6 cells/cell line in 100 AL serum-free DMEM; Invitrogen) on opposite flanks in the shoulder region, as described previously (22) . BxPC-3 cells were injected s.c. (n = 30 mice; 1.5 Â 10 6 cells in 100 AL 1:1 serum-free DMEM/Matrigel HC; BD Biosciences) in the left shoulder region. Studies commenced once tumors had reached a diameter of f0.5 cm.
Biodistribution studies. Radiotracers (f15-30 ACi) in saline/PBS (150-200 AL) were injected, and data were analyzed as previously described (n = 3 per time point; ref. 22) .
MicroPET imaging studies. Imaging data were collected and analyzed as previously described (22, 26) .
Standard uptake values (SUV) were computed by dividing the activity concentration in each voxel by the injected dose and then multiplying by the weight of the animal (26) . Maximum intensity projection (MIP) images were created by collapsing across one dimension with the maximum value in each column of voxels.
Autoradiography studies. Frozen tissue slices (tumor and surrounding tissue, 50 Am) in freezing medium (Tissue-Tek, Sakura Finetek) were exposed to a storage phosphor screen (GE Healthcare) overnight. The screen was read at a 50-Am resolution using a Storm 860 phosphorimager (GE Healthcare).
Statistical analysis. The data are reported as mean F SD. Two-tailed Student's t tests were performed to evaluate statistical significance. P < 0.05 was considered significant. In plots, the SD is smaller than the size of the symbol for some data points.
Results
PEGylated peptide ligands for A v B 6 . PEGylated A20FMDV2 variants were compared by ELISA to the established a v h 6 peptide ligand FBA-A20FMDV2 (Fig. 1) . They exhibited IC 50 of 3 to 6 nmol/L, similar to FBA-A20FMDV2. Inhibition of binding by the natural ligands to integrins a v h 3 , a v h 5 , a 5 h 1 , and a IIb h 3 required at least >1,000-fold higher concentrations of peptide (IC 50 >10 Amol/L), indicating that introduction of the PEG moieties did not have a deleterious effect on a v h 6 affinity and selectivity of A20FMDV2.
Integrin A v B 6 expression in human pancreatic cancer cell lines. Seven cell lines were screened by flow cytometry for a v h 6 expression (Fig. 2) . For reference, the melanoma cell line DX3puroh6, stably transduced to express a v h 6 , and its paired control line DX3puro, lacking expression of a v h 6 , were analyzed as positive and negative controls, respectively; both of these cell lines express similar levels of other integrins, including a v h 3 , a v h 5 , and a 5 h 1 (22) . BxPC-3 and Capan-2 showed high a v h 6 expression levels comparable with that of the positive control DX3puroh6. Capan-1 and L3.3 showed intermediate expression of a v h 6 , whereas MIA-PaCa2, Panc-1, and BCL-2cl9 showed expression levels equivalent to that of the negative control DX3puro.
Cell binding and internalization. Binding of the radiotracers 18 F]FBA-PEG 28 -A20FMDV2 for 1 hour in the presence of LAP, the radiotracer was able to efficiently compete for binding; binding levels in presence of 5 nmol/L LAP remained at z75% of those observed under LAP-free conditions ( Supplementary Fig. S4 ).
[ 28 ) n -A20FMDV2 (n = 0, 1, 2) biodistribution in the a v h 6 -endogenous BxPC-3 model. The feasibility of a v h 6 -targeted pancreatic tumor detection in vivo was evaluated in the BxPC-3 mouse model ( Fig. 4; Supplementary Table S1 ). For [ 18 F]FBA-A20FMDV2 initial uptake in and washout from the BxPC-3 xenograft (1 hour: 0.69 F 0.19% ID/g, 4 hours: 0.12 F 0.03% ID/g) were similar to those seen in the DX3puroh6 xenograft (1 hour: 0.66 F 0.09% ID/g, 4 hours: 0.06 F 0.00% ID/g). By contrast, for both of the PEGylated radiotracers uptake in the BxPC-3 xenograft 1 hour after injection was three to four times higher than in the DX3puroh6 xenograft, combined with excellent retention ([ F]FBA-(PEG 28 ) 2 -A20FMDV2, 1 hour: 1.57 F 0.25% ID/g, 4 hours: 2.08 F 0.37% ID/g). Autoradiography images obtained for the PEGylated radiotracers of BxPC-3 xenografts 1 hour after injection also showed preferential, tumor-specific uptake (Fig. 5) .
Renal clearance was the major route of elimination for all three radiotracers (Fig. 4 and data 28 -A20FMDV2 in healthy tissues compared favorably to the di-PEGylated radiotracer, resulting in a desirable clearing behavior resembling that observed for the non-PEGylated compound in healthy tissues; highest levels of radioactivity were detected in the kidneys and the gall bladder.
The BxPC-3/blood ratio remained relatively low for [ 18 F]FBA-A20FMDV2 (1 hour: 3.3:1, 4 hours: 7.0:1) and the BxPC-3/muscle ratio only reached statistically significant levels at the 4-hour time point (1 hour: 1.3:1, P = 0.38; 4 hours: 2.5:1, P = 0.02) because of more rapid washout from healthy tissues than from the tumor (Fig. 4, Supplementary Table S1 ). By comparison, improved BxPC-3/muscle ratios were seen for [ 18 
Importantly, levels of radioactivity in the BxPC-3 tumor were at least 4-fold higher than those for the pancreas itself for all radiotracers at all time points measured (Supplementary Table S1 The observations made for the peptide radiotracers during microPET imaging paralleled the results seen in the biodistribution study with preferential uptake noted in the tumor along with major uptake in kidneys, bladder (urine), and, for [ (27) .
MicroPET scans obtained with 
Discussion
The integrin a v h 6 has been identified as a prognostic biomarker for cancer of the colon, cervix, lung, and stomach (10) (11) (12) 21) . In addition, a v h 6 is reported to be expressed by many other types of carcinoma (13, 19) whereas corresponding normal tissue is weak or negative. Thus, a v h 6 represents an excellent target for imaging and therapy of carcinoma. We previously showed the ability to selectively image a v h 6 -expressing tumors in vivo using the PET radiotracer [ 18 F]FBA-A20FMDV2 (22) . While targeted imaging was achieved, low uptake and poor retention in the target tissue, together with metabolic instability, limited its general utility, leading us to explore strategies to improve pharmacokinetics. As introduction of PEG moieties (PEGylation) generally increases biological half-life, metabolic stability, and tumor-uptake (28, 29), we generated two variants of A20FMDV2 that included PEG moieties on the N-terminus of the peptide. These PEGylated variants of [ 18 F]FBA-A20FMDV2 were examined and compared with the parent compound. Monodisperse PEG polymers of moderate molecular weight [Fw(PEG 28 ) = 1.3 kDa] are short enough to be compatible with solid-phase chemistries yet large enough to be expected to approach a range with some beneficial in vivo (pharmacokinetic) properties. Additionally, owing to the monodisperse nature of the polymer, the final product is obtained as a single compound, allowing for precise characterization and batch-to-batch reproducibility, in contrast to mixtures containing polymer chains of different lengths encountered with the larger PEG products available.
As presented here, initial in vitro evaluation by ELISA indicated unchanged, high a v h 6 -specificity for the PEGylated compounds (Fig. 1) . Further binding experiments with the DX3puroh6 and DX3puro cell lines showed strong, a v h 6 -specific and PEG-dependent binding to the receptor expressed on cells in the presence of other related integrins (including a v h 3 , a v h 5 ,  and a 5 h 1 ; Fig. 3) . In vivo studies also showed improved, a v h 6 -targeted PEG-dependent tumor retention in the DX3puroh6/ DX3puro model (Supplementary Table S1 The DX3puroh6/DX3puro melanoma cancer model was generated by viral transduction of human h6 into human melanoma cells. To examine a model more closely resembling the actual human disease, we sought a cancer wherein the expression of a v h 6 was relevant to the disease and for which cell lines that had endogenous expression of a v h 6 existed; we chose to investigate pancreatic cancer. Sipos and colleagues (20) reported, as part of a study of gastroenteropancreatic adenocarcinomas, that a v h 6 expression was strongest in PDACs. Thus, of the 34 human PDAC samples analyzed, 32 (94%) received the maximum score (the mean score was 2.8/3.0, with none of the other carcinomas receiving a score over 1.5). These observations make a v h 6 a very appealing target for selective in vivo detection of pancreatic cancer. The possibility of detecting primary tumors and metastases earlier by imaging a v h 6 and, thus, directing therapy sooner may improve upon the very poor prognosis of this disease. In addition, recent studies associate strong expression of a v h 6 with poor prognosis ( for colon, lung, cervical, and stomach cancers; refs. 10-12, 21), so the relevance of our data is not restricted only to pancreatic cancer.
As shown here by flow cytometry (Fig. 2) , many common pancreatic carcinoma cell lines exhibit an a v h 6 profile that reflects expression seen for PDAC in the clinic (20) . In vitro cellbinding assays showed that [ 18 F]FBA-PEG 28 -A20FMDV2 performed equally well with the endogenously a v h 6 -expressing pancreatic BxPC-3 cell line and the transduced a v h 6 -expressing DX3puroh6 cell line, showing rapid and high binding together with significant internalization (Fig. 3) . Contrary to conditions in the in vivo environment, these assays were performed in the absence of natural ligands competing for binding to a v h 6 . We, therefore, sought to further show their relevance as predictors for in vivo performance by carrying out a binding assay in the presence of a biologically relevant a v h 6 ligand. LAP was chosen as it binds to a v h 6 with high affinity and has significance in the context of tumor biology (13, 18, 30) . In association with TGFh, particularly TGFh1, LAP binds to a v h 6 , thereby affecting signaling pathways understood to play significant roles in tumor development (18, 30) . We found that, even in the presence of 5 nmol/L LAP, the radiotracer, present at subpicomolar levels, was still able to efficiently bind to the cells (at z75% of binding observed under LAP-free conditions; Supplementary Fig. S4 ). The feasibility of evaluating a v h 6 -specific in vivo imaging radiotracers for pancreatic carcinoma was shown in a mouse model bearing BxPC-3 xenografts. In microPET images, the BxPC-3 tumors were clearly identifiable throughout. These data confirm that selective in vivo imaging of a v h 6 -expressing cancers is possible with cancers that endogenously express a v h 6 and not only those engineered to express it. Importantly for pancreatic imaging, the best pharmacokinetic behavior was observed for [ 2 -A20FMDV2 resulted only in a slight increase in tumor uptake, whereas, concurrently, washout of radioactivity from healthy tissue (except blood) was suppressed over the time span examined; particularly notable are the high and constant levels of radioactivity in the kidneys (Fig. 4) 2 -A20FMDV2 in healthy tissues, caused by introduction of the second PEG unit, had not been predicted. These observations seem to stand in contrast to the common belief that renal clearance remains highly efficient for compounds bearing small PEG units (under f30 kDa; refs. 28, 29) . Despite the comparatively small PEG units used in this study, the PEGylation of A20FMDV2 seemed to result in an ''enhanced permeation and retention'' effect toward the BxPC-3 tumors along with some improved radiotracer stability (29) . Positive effects of PEGylation on the in vivo stability of pharmaceuticals are generally recognized (28) . Likewise, in our study, only one major radioactive metabolite was found in HPLC samples of urine collected 1 28 -A20FMDV2 bound to BxPC-3 within 1 minute; Fig. 3B ) and significant, PEG-dependent internalization (approximately two thirds of bound activity were internalized at 1 hour; Fig. 3A) , delivery efficiency to the target likely was of principal importance for these radiotracers, provided that radioactive metabolites were rapidly cleared from the body, as observed particularly for [
18 F]FBA-PEG 28 -A20FMDV2. Taken together, these data suggest that rapid binding and internalization of the PEGylated radiotracers in cells are key to increased uptake and retention in the tumors. That being said, a detailed characterization of metabolites and further modification of the radiotracers remain of interest. They include selective deletion of redundant amino acids and replacement with unnatural amino acids in conjunction with multimeric radiotracers and incorporation of branched PEG. These approaches have already been successful in improving the pharmacokinetics of tracers for integrin a v h 3 (28, 31, 32) . For all three radiotracers and time points, the corresponding differences in uptake in BxPC-3 versus pancreas were statistically significant (A). For P values, see Supplementary Table S1 .
Paralleling the in vitro blocking studies with the a v h 6 -expressing cell lines, in vivo blocking experiments using the nonradioactive analogues showed a significant reduction of uptake in the BxPC-3 tumors. Before the blocking experiments, the animals were also evaluated by [ 18 F]FDG-PET, the standard radiotracer for PET imaging. Significantly, [ Better understanding of the biology of pancreatic cancer (34) and improved early, more accurate diagnosis are sorely needed. By combining detailed anatomical information with functional metabolic information, [ 18 F]FDG-PET/CT has shown some promise (5, 6, 8, 33) . However, the use of [ 18 F]FDG as radiotracer does not take advantage of the molecular biological differences of tumors beyond their increased (glucose) metabolism. The integrin a v h 6 is expressed strongly by most human pancreatic cancers (20) and is likely to be a prognostic indicator for this cancer. Therefore, it is clear that targeted in vivo imaging of a v h 6 will be a major improvement for preoperative staging and monitoring response to treatment for this lethal malignancy in humans. Using a metabolic probe ([ 
